Arcadia, Calif, October 10, 2000—Magnus & Co., a full-service marketing, public relations and communications agency, today announces that ID Biomedical Corporation, based in Vancouver, Canada, has selected the firm as its public relations agency of record. Magnus is tasked with expanding and enhancing the biopharmaceutical company's profile with the media and financial community in both the United States and Europe.

"The Magnus team is already proving to be a valuable asset to our company, delivering meaningful media results with high profile media," said Dr. Anthony Holler, president of ID Biomedical. "We're only two weeks into our contract, and the team has already secured meetings with major, targeted outlets such as Dow Jones, Reuters, and TheStreet.com."

"We are very proud of our new relationship with ID Biomedical," comments Carolyn Smith, president of Magnus. "The company is making significant contributions in the dynamic biomedical industry."

ID Biomedical is a publicly traded company (NASDAQ: IDBE) focused on implementing applications for its proprietary gene-based detection system, Cycling Probe™ Technology, in the rapidly emerging genomics and diagnostic industries. In addition, ID Vaccine, a fully owned subsidiary of ID Biomedical, leverages advances in modern gene technology to develop proprietary vaccine and immumotherapeutic products for potentially life-threatening diseases such as Tuberculosis, Group A Streptococcus (GAS), HIV/AIDS and E. Coli.

Magnus & Co., a California Corporation, is a full-service marketing, public relations and communications firm representing market leaders, emerging growth companies and funded startups in such diverse industries as high-tech, healthcare, consumer products, financial services, Internet, aviation, manufacturing, packaging, and telecommunications. Founded in 1990, the agency and its team of experienced professionals deliver results on a regional, national and international scale.